A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04586231. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
Study identification
- NCT ID
- NCT04586231
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 747 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 25, 2021 (Actual)
- Primary completion
- Feb 2, 2026 (Actual)
- Completion
- Feb 11, 2027 (Estimated)
- Last update posted
- Nov 6, 2026
2021 – 2027
United States locations
- U.S. sites
- 33
- U.S. states
- 23
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers ( Site 0077) | Chandler | Arizona | 85224 | — |
| Cedars Sinai Medical Center ( Site 0027) | Los Angeles | California | 90048 | — |
| UCLA Hematology/Oncology - Santa Monica ( Site 0048) | Los Angeles | California | 90404 | — |
| St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095) | Orange | California | 92868 | — |
| University of California, Irvine ( Site 0029) | Orange | California | 92868 | — |
| Providence Saint John's Health Center ( Site 0083) | Santa Monica | California | 90404 | — |
| Georgetown University Medical Center ( Site 0006) | Washington D.C. | District of Columbia | 20007 | — |
| AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003) | Orlando | Florida | 32804 | — |
| Orlando Health, Inc. ( Site 0035) | Orlando | Florida | 32806 | — |
| University Cancer & Blood Center, LLC ( Site 0057) | Athens | Georgia | 30607 | — |
| Emory University Hospital ( Site 0012) | Atlanta | Georgia | 30322 | — |
| Rush University Medical Center ( Site 0040) | Chicago | Illinois | 60607 | — |
| Illinois Cancer Care, PC ( Site 0008) | Peoria | Illinois | 61615 | — |
| Parkview Cancer Institute ( Site 0088) | Fort Wayne | Indiana | 46845 | — |
| Norton Cancer Institute - St. Matthews ( Site 0065) | Louisville | Kentucky | 40207 | — |
| Tulane University School of Medicine ( Site 0098) | New Orleans | Louisiana | 70112 | — |
| Lahey Hospital & Medical Center ( Site 0090) | Burlington | Massachusetts | 01805 | — |
| Cancer & Hematology Centers of Western Michigan ( Site 0018) | Grand Rapids | Michigan | 49503 | — |
| HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005) | Saint Louis Park | Minnesota | 55426 | — |
| University of Mississippi Medical Ctr ( Site 0037) | Jackson | Mississippi | 39213 | — |
| Cancer Partners of Nebraska ( Site 0086) | Lincoln | Nebraska | 68516 | — |
| Rutgers Cancer Institute of New Jersey ( Site 0078) | New Brunswick | New Jersey | 08903 | — |
| R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013) | Lake Success | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0055) | New York | New York | 10065 | — |
| Levine Cancer Institute ( Site 0004) | Charlotte | North Carolina | 28204 | — |
| Duke Cancer Institute ( Site 0096) | Durham | North Carolina | 27710 | — |
| Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056) | Allentown | Pennsylvania | 18103 | — |
| University of Texas, Southwestern Medical Center ( Site 0015) | Dallas | Texas | 75235 | — |
| Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001) | Salt Lake City | Utah | 84112 | — |
| University of Vermont Medical Center ( Site 0001) | Burlington | Vermont | 05401 | — |
| Blue Ridge Cancer Care - Roanoke ( Site 0043) | Roanoke | Virginia | 24014 | — |
| Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093) | Seattle | Washington | 98109 | — |
| Central Washington Health Services Association d/b/a Confluence Health ( Site 0061) | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 151 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04586231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2026 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.